Skip to main content
. 2017 Nov 21;8(64):107666–107677. doi: 10.18632/oncotarget.22587

Figure 3. Ivermectin inhibited the nuclear accumulation of YAP1 in vitro.

Figure 3

(A, C, D) Cells were treated with vehicle (DMSO) or 10 μM ivermectin for 24 h. (A) Left-top, Immunoblotting for nuclear expression of YAP1 and CTGF in MKN1 and MKN7 cells. Left-bottom, Densitometry quantification of the band intensities. *P < 0.05. Right, RT-qPCR of CTGF mRNA in MKN1 and MKN7 cells. *P < 0.05, ***P < 0.0005. (B) Left-top, Immunoblotting for nuclear expression of YAP1 in MKN1 cells treated with the indicated concentrations of ivermectin for 24 h. Right-top, Immunoblotting for nuclear expression of YAP1 in MKN1 cells treated with 10 μM ivermectin for the indicated times. Bottom, Densitometry quantification of the band intensities. **P < 0.005, ***P < 0.0005. (C) Immunoblotting for cytoplasmic YAP1 and phospho-YAP1 protein in MKN1 and MKN7 cells. (D) Immunofluorescence staining for YAP1 (red) in MKN1 and MKN7 cells. Scale bars, 20 μm.